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ABSTRACT
Primary cutaneous marginal zone lymphoma (PCMZL) is a B cell lymphoma with a very
low metastatic rate. Radiographic monitoring for internal involvement may be indicated
initially. Favored treatments include radiation and excision. Radiation has high risk of
local recurrence. Excision carries risk of infection and scarring. We report successful
long-term treatment of recurrent PCMZL via intralesional steroid injections into new
lesions as they arose. This was preferred by the patient over her prior radiation and
surgical treatments. Intralesional steroids have the advantages of being simple and
well tolerated, without exposure to ionizing radiation or to the infection and scarring
associated with surgery.
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INTRODUCTION
The incidence of primary cutaneous lymphomas
is approximately 10 cases per million inhabitants
per year, and they are the most frequent extranodal lymphomas.1 Cutaneous B cell lymphoma
(CBC L) comprises 25 to 30% of primary cutaneous
lymphoma, and data and guidelines on management
are lacking.2,3 CBC L prognosis differs greatly by
subtype. Indolent CBC L includes primary cutaneous
follicle centers lymphoma and primary cutaneous
marginal zone lymphoma (PCMZL). PCMZL does not
generally reduce lifespan.4
CASE REPORT
In 2008 a 53-year-old Caucasian woman presented
with a pink nodule on her right eyebrow. It was
initially shaved off, but recurred in 2009, at which
time punch biopsy revealed PCMZL. PET Scan, done
as per the current management guidelines by the
European Organization for Research and Treatment
of Cancer and International Society for Cutaneous
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Lymphoma, did not reveal systemic involvement.5
The eyebrow was treated with radiation therapy
with resolution. In 2011 the lesion recurred, was
re-biopsied, showing recurrent PCMZL. It was again
treated with radiation. In 2013 she developed three
new similar lesions, one on the right shoulder and
one on each arm. All three were surgically excised and
biopsy again revealed PCMZL. Although she denied
fever, chills, sweats or weight loss, she was referred
to oncology for restaging. Bone marrow biopsy and
a second PET scan revealed no concerning findings.
Oncology deemed her to be without systemic
involvement. One month after her oncology work up,
she presented with three new plaques, one on the
right forearm and two on the left shoulder. This time,
after being presented with the option of radiation
or surgery, she chose instead to receive intralesional
triamcinolone injections. The lesions received a total
of 0.85 mL of 5 mg / cc triamcinolone. The procedure
was well tolerated. Lesions improved dramatically.
Six weeks later she was again injected, this time 0.2
mL total. Lesions fully resolved. Over the next three
and a half years she was seen at four to eight week
intervals and any new lesions were injected as above.
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FIG A: Elevated pink nodule on eyebrow with slight central scale. Eyebrow is preserved but on palpation there is
the feeling of depth. This is after failure of radiation two
times and excision.

During the next two years, the visits were gradually
decreased to six-month intervals. All injections
were well tolerated. The only adverse effects were
indentations at some of the injection sites; the
patient was not bothered by this.
DISCUSSION
Because systemic involvement is seldom seen,
PCMZL is typically treated with radiation, excision,
and/or rituximab (anti-CD20 monoclonal antibody).6
Rituximab carries risk of serious side effects.7 Surgery
carries risk of infection as well as scar, and data
on margins and recurrence is lacking.4 Radiation
therefore has been a mainstay of PCMZL therapy.
Unfortunately, radiation carries reported recurrence
risks ranging from 25 to 63%.1,8 Topical steroids can be
tried as well but show limited efficacy.
Intralesional steroids therefore present a reasonable
treatment. They are more cost effective and easier to
administer than the other therapies currently used
for the treatment of PCMZL.9 Reported risks include
recurrence, atrophy, and temporary erythema.10
The patient in this report experienced limited
local atrophy. She preferred this to the scars left
by plastic surgery excision. Unlike her experience
with radiation, none of the lesions treated with
intralesional steroids recurred.
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FIG B: Intralesional steroids caused rapid resolution without scar and without recurrence for 2 years.

Current management guidelines by the European
Organization for Research and Treatment of Cancer
and International Society for Cutaneous Lymphoma
do not mention intralesional corticosteroids in
the treatment of PCMZL, even though there have
been a few reports, including ours, of successful
treatment with intralesional steroids.5,9,10,11 We
propose that close monitoring with intralesional
steroid injection of new lesions may be an effective
and well-tolerated way to treat chronic PCMZL, and
that larger controlled trials of this therapy should be
encouraged.
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